UnknownUnicorn2993086

EXPOSED by Citron.

Short
NASDAQ:INGN   Inogen, Inc
1.) Average age of consumers are 75+, only 10% of its sales come from medicare. <---- UNACCEPTABLE

2.) WRONG INFO GIVEN BY RESELLERS TO CUSTOMERS.

Per Citron:
Citron estimates that Inogen sells about 90% of its POC units vs. only renting about 10% through Medicare. Assuming 40% of POC units were rented through Medicare, Inogen’s revenue would decline by about 20% while EPS would decline by about 80% due to the negative mix shift to Medicare’s much lower margins. Evidently, the multiple would see meaningful contraction as well.
Citron jumps into muddy waters and assigns a conservative $46 target on Inogen.


“On July 11, 2018, CMS released a new proposal to change the payment rules for Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS), including our portable oxygen concentrators. This includes a proposal that when the current competitive bidding contracts expire December 31, 2018, beneficiaries can obtain DMEPOS items from any enrolled Medicare supplier. ”
Now that any DME can offer you a portable oxygen concentrator, Inogen will get much fewer Medicare leads that can be turned into cash sales.

PLEASE READ Citron's report: citronresearch.com/w...n’s-Sale-Tactics.pdf

Per Muddy Water:
"We believe management has created egregiously false narrative re TAM & growth. Real TAM is ~1. 3M users, not 3M as claimed. TAM is shrinking, NOT growing at 7%-10%."
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.